Zacks Research Has Bearish Estimate for Exelixis Q1 Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Analysts at Zacks Research lowered their Q1 2025 EPS estimates for shares of Exelixis in a research note issued on Monday, March 3rd. Zacks Research analyst E. Bagri now expects that the biotechnology company will post earnings per share of $0.35 for the quarter, down from their previous estimate of $0.40. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q3 2025 earnings at $0.50 EPS, FY2025 earnings at $1.92 EPS, Q1 2026 earnings at $0.49 EPS, Q2 2026 earnings at $0.58 EPS, Q3 2026 earnings at $0.58 EPS, Q4 2026 earnings at $0.81 EPS and FY2026 earnings at $2.47 EPS.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%.

Several other brokerages also recently commented on EXEL. Brookline Capital Management assumed coverage on shares of Exelixis in a research report on Monday, December 23rd. They set a “buy” rating for the company. Stephens reaffirmed an “equal weight” rating and set a $29.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. BMO Capital Markets downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and raised their price objective for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. Piper Sandler raised their price objective on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus raised their price objective on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.24.

Exelixis Stock Performance

Exelixis stock opened at $38.58 on Thursday. Exelixis has a 52-week low of $20.14 and a 52-week high of $39.30. The firm has a 50 day moving average price of $34.90 and a two-hundred day moving average price of $31.96. The firm has a market cap of $10.80 billion, a price-to-earnings ratio of 21.80, a PEG ratio of 1.13 and a beta of 0.57.

Institutional Investors Weigh In On Exelixis

Hedge funds have recently made changes to their positions in the business. Coppell Advisory Solutions LLC bought a new stake in shares of Exelixis during the 4th quarter worth $25,000. Colonial Trust Co SC raised its stake in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 765 shares during the period. USA Financial Formulas bought a new stake in shares of Exelixis during the 4th quarter worth $32,000. Principal Securities Inc. raised its stake in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 373 shares during the period. Finally, Kestra Investment Management LLC bought a new stake in shares of Exelixis during the 4th quarter worth $39,000. 85.27% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Exelixis

In other Exelixis news, CFO Christopher J. Senner sold 29,314 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the transaction, the chief financial officer now directly owns 779,607 shares in the company, valued at approximately $28,174,996.98. This trade represents a 3.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now owns 30,406 shares in the company, valued at approximately $1,060,561.28. This trade represents a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 140,343 shares of company stock worth $5,177,234. Corporate insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.